U.S. markets open in 6 hours 47 minutes
  • S&P Futures

    4,004.25
    +1.00 (+0.02%)
     
  • Dow Futures

    34,008.00
    +22.00 (+0.06%)
     
  • Nasdaq Futures

    11,797.00
    -8.75 (-0.07%)
     
  • Russell 2000 Futures

    1,843.40
    +1.50 (+0.08%)
     
  • Crude Oil

    77.60
    +0.67 (+0.87%)
     
  • Gold

    1,782.50
    +1.20 (+0.07%)
     
  • Silver

    22.54
    +0.12 (+0.55%)
     
  • EUR/USD

    1.0489
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    3.5990
    0.0000 (0.00%)
     
  • Vix

    20.75
    +1.69 (+8.87%)
     
  • GBP/USD

    1.2203
    +0.0009 (+0.07%)
     
  • USD/JPY

    137.0710
    +0.3860 (+0.28%)
     
  • BTC-USD

    17,011.83
    -315.07 (-1.82%)
     
  • CMC Crypto 200

    401.75
    -9.47 (-2.30%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,885.87
    +65.47 (+0.24%)
     

Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference

Surface Oncology, Inc.
Surface Oncology, Inc.

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, “IOs Wide Open - Opportunity and Challenges in Immuno-Oncology” at the 2022 Wedbush PacGrow Healthcare Conference. The panel discussion will take place on Tuesday, August 9, 2022, at 8:00 am ET.

A live webcast of the discussion may be accessed by visiting the Investors & Media section of the Surface Oncology website at www.surfaceoncology.com. A replay of the webcast will be available on the company’s website following the presentation.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational, cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com